Mycophenolate mofetil improves long-term graft survival following renal transplantation in patients experiencing delayed graft function

Transplantation Proceedings

Volumn 31, Issue 1-2, 1999, Pages 322-323

  Cho, S ^a,b,c   Hodge, E ^a,b,c   Navarro, M ^a,b,c  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^b Austin Diagnostic Clinic Hepatitis Center   (United States)

^c HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

CONFERENCE PAPER; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; PRIORITY JOURNAL;

ADULT; ANTILYMPHOCYTE SERUM; AZATHIOPRINE; DRUG THERAPY, COMBINATION; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MUROMONAB-CD3; MYCOPHENOLIC ACID; RISK FACTORS; TIME FACTORS;

EID: 0032985109     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0041-1345(98)01645-5     Document Type: Conference Paper

References (4)

1. Ojo A.O., Wolfe R.A., Held P.J., et al. Transplantation. 63:1997;968.
2. Koning O.H.J., Ploeg R.J., Van Bockel J.H., et al. Transplantation. 63:1997;1620.
3. Shoskes D, Cecka M: In Clinical Transplants 1997; 1997, p 297.
4. Halloran P., Mathew T., Tomlanovich S., et al. Transplantation. 63:1997;39.